Aevi Genomic Medicine, LLC
DelistedCIK 1138776fmd_00G21CXGD2BY6E8VN3WG9NBVKZManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2001 to Sep 30, 2019, 47 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | – | 0 | 5 | 5 | 7 | 8 | 15 | 28 | 8 | 7 |
| Operating income | – | (3) | (10) | (13) | (18) | (19) | (37) | (42) | (35) | (31) |
| Interest expense | – | – | 0 | 0 | 0 | – | – | – | – | – |
| Interest and investment income | – | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | – | (4) | (8) | (15) | (17) | (18) | (38) | (42) | (35) | (31) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (4) | (8) | (15) | (17) | (18) | (38) | (42) | (35) | (31) |
| Net income | (7) | (4) | (8) | (15) | (17) | (18) | (38) | (42) | (35) | (31) |
| Net income to common shareholders | – | – | 0 | 15 | 17 | 18 | 38 | 42 | – | – |